EnteroBiotix: EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)

GLASGOW, Scotland, April 03, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the first patient has been dosed in a multi-centre randomised double-blind...